Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice

Journal of General Virology

Volumn 88, Issue 9, 2007, Pages 2473-2478

  Gómez, Carmen Elena ^a   Nájera, José Luis ^a   Domingo Gil, Elena ^a   Ochoa Callejero, Laura ^b   González Aseguinolaza, Gloria ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; RECOMBINANT VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOLOGY; INOCULATION; MOUSE; NONHUMAN; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; REPORTER GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; GENES, REPORTER; KINETICS; LUCIFERASES; MICE; POXVIRIDAE; VACCINES, ATTENUATED; VIRAL VACCINES;

ANIMALIA; MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 34548214302     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83018-0     Document Type: Article

References (25)

1. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Monteflori, D. C., Xu, Y., Herndon, J. G. & other authors (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
2. Antoine, G., Scheiflinger, F., Domer, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
3. Bonnet, M. C., Tartaglia, J., Verdier, F., Kourilsky, P., Lindberg, A., Klein, M. & Moingeon, P. (2000). Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74, 11-25.
4. Chahroudi, A., Chavan, R., Kozyr, N., Waller, E. K., Silvestri, G. & Feinberg, M. B. (2005). Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79, 10397-10407.
5. Cox, W. I., Tartaglia, J. & Paoletti, E. (1993). Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195, 845-850.
6. Didierlaurent, A., Ramirez, J. C., Gherardi, M., Zimmerli, S. C., Graf, M., Orbea, H. A., Pantaleo, G., Wagner, R., Esteban, M. & other authors (2004). Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22, 3395-3403.
7. Doyle, T. C., Burns, S. M. & Contag, C. H. (2004). In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol 6, 303-317.
8. Edinger, M., Sweeney, T. J., Tucker, A. A., Olomu, A. B., Negrin, R. S. & Contag, C. H. (1999). Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1, 303-310.
9. Gherardi, M. M., Najera, J. L., Perez-Jimenez, E., Guerra, S., Garcia-Sastre, A. & Esteban, M. (2003). Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 77, 7048-7057.
10. + T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ. Virus Res 105, 11-22.
11. Gomez, C. E., Najera, J. L., Jimenez, E. P., Jimenez, V., Wagner, R., Graf, M., Frachette, M. J., Liljestrom, P., Pantaleo, G. & Esteban, M. (2007a). Head-to-head comparison on the immunogenicity of two HIV/ AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25, 2863-2885.
12. Gomez, C. E., Najera, J. L., Jimenez, V., Bieler, K., Wild, J., Kostic, L., Heidari, S., Chen, M., Frachette, M. J. & other authors (2007b). Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25, 1969-1992.
13. Guerra, S., Lopez-Fernandez, L. A., Conde, R., Pascual-Montano, A., Harshman, K. & Esteban, M. (2004). Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 78, 5820-5834.
14. Guerra, S., Lopez-Fernandez, L. A., Pascual-Montano, A., Najera, J. L., Zaballos, A. & Esteban, M. (2006). Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-κB-responsive genes in infected HeLa cells. J Virol 80, 985-998.
15. + T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 167, 7180-7191.
16. Mayr, A., Stickl, H., Muller, H. K, Danner, K. & Singer, H. (1978). The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol [B] 167, 375-390 (in German).
17. Najera, J. L., Gomez, C. E., Domingo-Gil, E., Gherardi, M. M. & Esteban, M. (2006). Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80, 6033-6047.
18. Ramirez, J. C., Gherardi, M. M. & Esteban, M. (2000). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74, 923-933.
19. Ray, P., De, A., Min, J. J., Tsien, R. Y. & Gambhir, S. S. (2004). Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64, 1323-1330.
20. Rodriguez, J. F., Rodriguez, D., Rodriguez, J. R., McGowan, E. B. & Esteban, M. (1988). Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci U S A 85, 1667-1671.
21. Sadikot, R. T. & Blackwell, T. S. (2005). Bioluminescence imaging. Proc Am Thorac Soc 2, 537-540.
22. Tartaglia, J., Cox, W. I., Taylor, J., Perkus, M., Riviera, M., Meignier, B. & Paoletti, E. (1992a). Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 8, 1445-1447.
23. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet J. C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B. & other authors (1992b). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
24. Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L. & other authors (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102, 4836-4841.
25. + T cells. Virology 280, 155-159.